Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short-term Investments: 2020-2024

Historic Short-term Investments for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to $57.8 million.

  • Mirum Pharmaceuticals' Short-term Investments rose 52.14% to $93.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.5 million, marking a year-over-year increase of 52.14%. This contributed to the annual value of $57.8 million for FY2024, which is N/A change from last year.
  • Mirum Pharmaceuticals' Short-term Investments amounted to $57.8 million in FY2024, which was down 53.27% from $123.7 million recorded in FY2022.
  • Mirum Pharmaceuticals' Short-term Investments' 5-year high stood at $125.2 million during FY2021, with a 5-year trough of $57.8 million in FY2024.
  • Over the past 2 years, Mirum Pharmaceuticals' median Short-term Investments value was $90.8 million (recorded in 2022), while the average stood at $90.8 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Short-term Investments skyrocketed by 39.52% in 2021 and then decreased by 1.19% in 2022.
  • Mirum Pharmaceuticals' Short-term Investments (Yearly) stood at $89.7 million in 2020, then soared by 39.52% to $125.2 million in 2021, then decreased by 1.19% to $123.7 million in 2022, then reached $57.8 million in 2024.